bioAffinity Technologies Hosts First CyPath Lung Exhibition Under AvMEDICAL Deal

What Happened

• bioAffinity Technologies, Inc. (BIAF) announced in an 8-K (Item 8.01) on September 30, 2026 that it delivered the first joint exhibition of its CyPath Lung product under the company’s recently announced distribution agreement with AvMEDICAL (a Service-Disabled Veteran-Owned Small Business).
• The joint exhibition was presented to more than 300 physicians, healthcare professionals and VA leaders at the National Association of Veterans’ Research and Education Foundations (NAVREF) Annual Conference in Arlington, Virginia. A press release describing the event is attached to the filing as Exhibit 99.1.

Key Details

• Filing type: Form 8-K (Item 8.01 — Other Events), filed September 30, 2026.
• Event: First joint exhibition of CyPath Lung under the AvMEDICAL distribution agreement.
• Audience/scale: Presented to 300+ physicians, healthcare professionals and VA leaders at NAVREF Annual Conference (Arlington, VA).
• Exhibit: Press release attached as Exhibit 99.1 and incorporated by reference.

Why It Matters

• This marks the first public demonstration of CyPath Lung under the new AvMEDICAL distribution arrangement, indicating initial commercial and outreach activity tied to that partnership.
• Exposure to a large group of VA and healthcare stakeholders could help adoption within VA and veteran-focused networks, which is relevant given AvMEDICAL’s SDVOSB status and potential access to VA channels.
• For investors, the filing documents operational progress (marketing/exposure) rather than financial results; monitor future filings for sales, revenue, or firm confirmation of distribution rollout and commercial milestones.